PT  - JOURNAL ARTICLE
AU  - Lemmermann, NA
AU  - Lieb, B
AU  - Laufs, T
AU  - Renzaho, A
AU  - Runkel, S
AU  - Kohnen, W
AU  - Linke, M
AU  - Gerber, S
AU  - Schweiger, S
AU  - Michel, A
AU  - Bikar, S-E
AU  - Plachter, B
AU  - Hankeln, T
TI  - SARS-CoV-2 genome surveillance in Mainz, Germany, reveals convergent origin of the N501Y spike mutation in a hospital setting
AID  - 10.1101/2021.02.11.21251324
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.11.21251324
4099  - http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251324.short
4100  - http://medrxiv.org/content/early/2021/02/12/2021.02.11.21251324.full
AB  - While establishing a regional SARS-Cov-2 variant surveillance by genome sequencing, we have identified three infected individuals in a clinical setting (two long-term hospitalized patients and a nurse) that shared the spike N501Y mutation within a genotype background distinct from the current viral variants of concern. We suggest that the adaptive N501Y mutation, known to increase SARS-CoV-2 transmissibility, arose by convergent evolution around December in Mainz, Germany. Hospitalized patients with a compromised immune system may be a potential source of novel viral variants, which calls for monitoring viral evolution by genome sequencing in clinical settings.Competing Interest StatementBL, TL and SEB are employees of StarSEQ GmbH, Mainz.Funding Statementthis study was not external fundedAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For this study an exemption was provided by the local Ethics Committee of the Landesaerztekammer Rheinland-Pfalz, Germany in accordance with the Declaration of Helsinki. All data were collected in the course of regular clinical diagnostics.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesall data are available upon request